Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 3/20 | 0.51 |
| ▸ | CHRNA3 known ✓ | P32297 | 3/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.97 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | BPTF | Q12830 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2491811 | 1.00 | CHRNB2 (0.97) | CHRNB2CHRNA4KMT2ABPTFCHRNB4 | |
| SCHEMBL5036654 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4KMT2ABPTFCHRNB4 | |
| SCHEMBL6626896 | 0.89 | CHRNB2 (0.82) | CHRNB2CHRNA4KMT2ABPTFCHRNB4 | |
| SCHEMBL7687469 | 0.80 | CHRNB2 (0.68) | CHRNB2CHRNA4KMT2ABPTFCHRNB4 | |
| Fumaric Acid SCHEMBL27563609 | 0.79 | CHRNB2 (0.65) | CHRNB2CHRNA4KMT2ABPTFCHRNB4 | |
| SCHEMBL31104892 | 0.78 | CHRNB2 (0.66) | CHRNB2CHRNA4KMT2ABPTFCHRNB4 | |
| SCHEMBL10756477 | 0.78 | CHRNB2 (0.66) | CHRNB2CHRNA4KMT2ABPTFCHRNB4 | |
| SCHEMBL17695874 | 0.78 | CHRNB2 (0.66) | CHRNB2CHRNA4KMT2ACHRNB4CHRNA3 | |
| SCHEMBL31119073 | 0.76 | CHRNB2 (0.63) | CHRNB2CHRNA4KMT2ABPTFCHRNB4 | |
| Hydrochloric Acid SCHEMBL5041501 | 0.75 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173318-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2024-05-30 | — | — | US | claimed |
| WO-2023229993-A1 | OPHTHALMIC FORMULATION CAPABLE OF DELIVERING METFORMIN TO CHOROID RPE AND RETINA | CURATIVE BIOTECHNOLOGY, INC. (US) | 2023-11-30 | — | — | WO | claimed |
| EP-4027985-A1 | DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2022-07-20 | — | — | EP | claimed |
| CN-114650813-A | Druggable targets for the treatment of retinal degeneration | 美国卫生和人力服务部 | 2022-06-21 | — | — | CN | claimed |
| US-12576080-B2 | Use of varenicline for treating ocular conditions | Oyster Point Pharma, Inc. | 2026-03-17 | — | — | US | disclosed |
| EP-4680243-A1 | METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250275963-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250255865-A1 | METHODS OF TREATING OCULAR CONDITIONS | OYSTER POINT PHARMA INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250235449-A1 | METHODS OF TREATING OCULAR CONDITIONS | OYSTER POINT PHARMA INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2025-05-15 | — | — | US | disclosed |
| EP-3848028-B9 | METHODS OF TREATING OCULAR CONDITIONS | OYSTER POINT PHARMA INC (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20230226052-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226054-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220339127-A1 | DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-10-27 | — | — | US | disclosed |
| US-20220233528-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC. | 2022-07-28 | — | — | US | disclosed |
| EP-4027985-A1 | DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-4017874-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | Coda Biotherapeutics, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114650813-A | Druggable targets for the treatment of retinal degeneration | 美国卫生和人力服务部 | 2022-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576080-B2 | Use of varenicline for treating ocular conditions | PDE6D, PDE11A, PDE10A | CHRNB4 306/4885CHRNA3 395/4885CHRNB2 218/4885 |
| US-20220233528-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB4 1806/4885CHRNA3 2020/4885CHRNB2 1787/4885 |
| US-20250235449-A1 | METHODS OF TREATING OCULAR CONDITIONS | CYSLTR2, ASAH2, AQP4 | CHRNB4 516/4885CHRNA3 540/4885CHRNB2 396/4885 |
| US-20250275963-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB4 1806/4885CHRNA3 2020/4885CHRNB2 1787/4885 |
| US-20240173318-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB4 1806/4885CHRNA3 2020/4885CHRNB2 1787/4885 |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | CHRNB4 8/4885CHRNA3 10/4885CHRNB2 1/4885 |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | CHRNB4 7/4885CHRNA3 9/4885CHRNB2 5/4885 |
| US-20230226054-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB4 1806/4885CHRNA3 2020/4885CHRNB2 1787/4885 |
| US-20250255865-A1 | METHODS OF TREATING OCULAR CONDITIONS | CYSLTR2, ASAH2, AQP4 | CHRNB4 516/4885CHRNA3 540/4885CHRNB2 396/4885 |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | CHRNB4 8/4885CHRNA3 10/4885CHRNB2 1/4885 |
| US-20230226052-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB4 1806/4885CHRNA3 2020/4885CHRNB2 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.